Both ATP and Mg2+ are Required for High-Affinity Binding of Indolmycin to Human Mitochondrial Tryptophanyl-tRNA Synthetase

This study reveals that human mitochondrial tryptophanyl-tRNA synthetase requires both ATP and Mg2+ to achieve high-affinity indolmycin binding through a reinforced ground-state metal coordination mechanism that structurally and thermodynamically mimics bacterial enzymes, contrasting sharply with the binding properties of human cytoplasmic TrpRS.

The Gist

The Big Picture: A Case of Mistaken Identity

Imagine your body is a massive, bustling factory. Inside this factory, there are two different types of assembly lines: one is the Main Factory Floor (the cytoplasm), and the other is the Power Plant (the mitochondria). Both lines need to build a specific product called "Tryptophan-tRNA" to keep the factory running.

To do this, they use a specialized machine called TrpRS (Tryptophanyl-tRNA Synthetase).

• The Main Factory Machine (Human Cytoplasmic TrpRS): This machine is very picky. It has a complex locking mechanism that only accepts the real ingredient (Tryptophan) and rejects look-alikes.
• The Power Plant Machine (Human Mitochondrial TrpRS): This machine is an ancient relic. It looks and acts very much like the machines used by bacteria (the original power plants before they became part of our cells). It is less picky and shares a lot of DNA with bacterial machines.

The Problem: The "Trojan Horse" Drug

Scientists have a drug called Indolmycin. Think of this drug as a "Trojan Horse." It looks almost exactly like the real ingredient (Tryptophan), but it has a special "trap" built into it (a ring structure called an oxazolinone).

• What it does to Bacteria: When Indolmycin enters a bacterial machine, it fits perfectly. It grabs the machine's "power source" (ATP and a metal ion called Magnesium) and locks them in a position where the machine can't work. The bacteria stop producing, and the infection dies.
• What it does to the Main Factory: The Main Factory machine is so different that Indolmycin doesn't fit well at all. It's like trying to put a square peg in a round hole. The drug bounces off, leaving the human factory safe.

The Question: What about the Power Plant (Mitochondria)? Since it looks like the bacterial machine, will the drug accidentally shut down the human Power Plant, causing energy failure and disease?

The Discovery: The "Lock and Key" Investigation

The researchers in this paper decided to take a super-magnified X-ray picture (a crystal structure) of the Human Mitochondrial machine with the drug and the power source all stuck together. They wanted to see exactly how they fit.

Here is what they found, using simple analogies:

1. The "Power Couple" Effect (ATP + Magnesium)
Imagine the machine needs a specific key (ATP) and a specific battery (Magnesium) to work.

• The researchers found that the drug (Indolmycin) is a terrible fit on its own.
• However, if the machine already has the Key and the Battery inserted, the drug snaps into place like a magnet.
• The Analogy: It's like a security system. The door (the machine) won't lock unless the security guard (ATP) and the badge (Magnesium) are already standing there. Once they are in place, the drug slides in and jams the gears. Without the guard and badge, the drug just slides right past.

2. The "Off-Path" Trap
When the drug, the key, and the battery all come together, they form a weird, stable shape.

• The Analogy: Imagine a car engine. Normally, the spark plug fires to move the car forward. But this drug forces the spark plug to fire in a way that locks the engine in "Park" permanently. The engine is full of energy, but it can't move. The machine is stuck in a "ground state" where it can't do its job.

3. The Human Mitochondrial Machine is a "Bacterial Cousin"
The X-ray pictures showed that the Human Mitochondrial machine uses the exact same tricks as the bacterial machine to hold the drug.

• It uses the same "fingers" (amino acids) to grab the drug.
• It uses the same "magnetic pull" (metal ions) to lock the drug in place.
• The Result: The drug does jam the human Power Plant, but not quite as tightly as it jams the bacterial one. It's about 40 times weaker in humans than in bacteria.

Why Does This Matter?

This is a double-edged sword, but mostly good news for drug design:

1. The Bad News: Because the human Power Plant machine is so similar to the bacterial one, antibiotics that target bacteria can sometimes accidentally hurt our mitochondria. This can lead to side effects or even diseases like Parkinson's (which is linked to mitochondrial damage).
2. The Good News: The researchers found a "sweet spot." The drug binds to bacteria very tightly, but to the human Power Plant less tightly (though still enough to be a concern).
   • The Analogy: It's like a lockpick that opens the bacterial door instantly, but only jiggles the human door slightly.
   • This gives scientists a "quantitative window." They know exactly how much the drug binds to the human machine versus the bacterial one. This helps them design new drugs that are even more picky—ones that jam the bacterial machine completely but slide right off the human machine.

The "Magic" Ingredient: The Metal Ion

The most important discovery in the paper is that Magnesium (the metal ion) is the glue.

• Without Magnesium, the drug doesn't stick well.
• With Magnesium (and ATP), the drug sticks 100 times tighter.
• The Analogy: Think of the drug as a piece of Velcro. On its own, it's weak. But if you attach it to a metal plate (Magnesium) that is already stuck to the wall (ATP), it becomes incredibly strong. The drug works by hijacking this metal plate to lock the machine down.

Summary

This paper is like a detective story where scientists used X-ray vision to see how a drug interacts with our body's power plants. They discovered that our power plants are so similar to bacterial ones that the drug can jam them, but not quite as effectively as it jams the bacteria.

The key takeaway is that Magnesium and ATP are required for the drug to work. By understanding exactly how these three things fit together, scientists can now design better antibiotics that kill bacteria without accidentally turning off our own human power plants.

Technical Summary

1. Problem Statement

• Context: The development of new antibiotics is hindered by drug resistance and the risk of off-target toxicity. Many antibiotics target bacterial aminoacyl-tRNA synthetases (aaRS), but these enzymes often have human homologs. Mitochondrial aaRSs are particularly vulnerable because they evolved from bacterial ancestors and share high sequence/structural homology with bacterial enzymes, unlike their cytosolic counterparts.
• Specific Challenge: Tryptophanyl-tRNA synthetase (TrpRS) is a potential antibacterial target. The natural inhibitor indolmycin binds tightly to bacterial TrpRS (e.g., Bacillus stearothermophilus, BsTrpRS) but poorly to human cytosolic TrpRS (HcTrpRS). However, the structural and mechanistic basis for indolmycin's interaction with human mitochondrial TrpRS (HmtTrpRS) was unknown.
• Knowledge Gap: While HmtTrpRS shares ~41% sequence identity with bacterial TrpRS (vs. 14% with HcTrpRS), no high-resolution structural data existed to explain whether HmtTrpRS is susceptible to indolmycin inhibition and how the enzyme coordinates ATP and metal ions during this process.

2. Methodology

The study employed a multi-faceted approach combining structural biology, kinetics, and thermodynamics:

• Protein Engineering & Purification: The gene for HmtTrpRS (residues 19–360, removing the mitochondrial targeting signal) was cloned into a pET28b vector with a TEV cleavage site. The protein was expressed in E. coli with chaperones (GroEL/ES), purified via Ni-NTA affinity chromatography, TEV cleavage, and size-exclusion chromatography.
• X-ray Crystallography: Crystals of HmtTrpRS were grown in complex with ATP, indolmycin, and Mn²⁺ (used as a surrogate for Mg²⁺ to exploit anomalous scattering for phasing). Data were collected at the Advanced Photon Source (SER-CAT 22-ID). The structure was solved by molecular replacement using the BsTrpRS structure as a template.
• Isothermal Titration Calorimetry (ITC): Experiments were conducted at 37°C to measure binding thermodynamics. Ligands (indolmycin, ATP, Mg²⁺) were titrated into the protein to determine dissociation constants ($K_d$) and Gibbs free energy changes ($\Delta G$) under various conditions (ligand-free, ATP-bound, Mg²⁺•ATP-bound).
• Kinetic Assays: Michaelis-Menten kinetics were performed using radiolabeled [³²P]PPi to determine $k_{cat}$ and $K_M$ for wild-type and site-directed mutants (Q42A, H48T, K145A, D181A, K229A). Inhibition constants ($K_i$) for indolmycin were derived from competitive inhibition models.
• Thermodynamic Modeling: Linear regression and thermodynamic cycle analysis were used to calculate coupling free energies ($\Delta\Delta G_{int}$) between ATP, Mg²⁺, and the oxazolinone (OXA) moiety of indolmycin.

3. Key Contributions

• First High-Resolution Structure: Provided the first 1.82 Å crystal structure of HmtTrpRS in a ternary complex with ATP, indolmycin, and a metal ion (Mn²⁺).
• Mechanistic Validation: Confirmed that HmtTrpRS utilizes a bacterial-like mechanism for indolmycin inhibition, distinct from the human cytosolic isoform.
• Thermodynamic Coupling: Demonstrated that high-affinity binding of indolmycin is strictly dependent on the simultaneous presence of both ATP and Mg²⁺, revealing a synergistic energetic coupling not previously quantified for this system.
• Structural Determinants: Identified specific residues (Asp167, His77, Gln182) and motifs (KMSKS, GxDQ) responsible for the "off-path" ground-state stabilization of the inhibitor.

4. Key Results

Structural Findings

• Dimeric State: Unlike the monomeric BsTrpRS, HmtTrpRS crystallized as a dimer in the asymmetric unit. The interface involves the burial of a tryptophan side chain (Trp125) and a hydrogen bond between Leu76 and Trp125.
• Active Site Architecture:
  • Indolmycin Binding: The indole nitrogen is recognized by Asp167 (homologous to BsTrpRS Asp132) and Gln170. The oxazolinone (OXA) ring is stabilized by hydrogen bonds from His77 and Gln182, and water-mediated interactions with the metal.
  • ATP/Metal Coordination: ATP binds in an extended conformation. The catalytic metal (Mn²⁺) is hexavalently coordinated by oxygen atoms from all three phosphate groups and water molecules.
  • The "Off-Path" State: The OXA ring of indolmycin forms a unique coordination with the metal ion that locks the metal in a stable ground-state configuration. This prevents the metal from adopting the high-energy geometry required for catalysis (tryptophan activation).
• Comparison: The HmtTrpRS active site closely mimics BsTrpRS but differs significantly from HcTrpRS (which lacks the Asp167 homolog and has a bent ATP conformation).

Thermodynamic & Kinetic Findings

• Affinity Requirements:
  • Indolmycin binds HmtTrpRS with a $K_d$ of ~3.9 µM (ligand-free).
  • Pre-binding ATP alone increases affinity 3-fold ($K_d$ ~1.3 µM).
  • Pre-binding Mg²⁺•ATP increases affinity ~100-fold, resulting in a $K_d$ of 39.6 nM.
• Energetic Coupling:
  • The binding of Mg²⁺•ATP stabilizes indolmycin binding by ~ -3 kcal/mol relative to ATP alone.
  • Thermodynamic cycle analysis revealed a significant Gibbs coupling free energy ($\Delta\Delta G_{int}$) between the OXA moiety of indolmycin and the Mg²⁺•ATP complex.
  • The OXA moiety is critical: Tryptophanamide (lacking OXA) does not show this synergistic stabilization; in fact, ATP alone slightly destabilizes tryptophanamide binding.
• Mutational Analysis:
  • Mutations in residues interacting with ATP (Q42, D181, K229) or the mobile loop (K145) had minimal effect on ATP $K_M$ but drastically reduced $k_{cat}$ (up to 230-fold reduction).
  • This confirms that these residues are critical for transition state stabilization rather than ground-state substrate binding, consistent with the bacterial mechanism.

5. Significance

• Antibiotic Selectivity Window: The study quantifies a "selectivity window." HmtTrpRS is ~40-fold less sensitive to indolmycin than bacterial TrpRS but ~10,000-fold more sensitive than human cytosolic TrpRS. This suggests that while HmtTrpRS is a potential off-target, there is a quantitative basis for designing bacterio-specific inhibitors that exploit the unique Mg²⁺•ATP coupling mechanism.
• Mitochondrial Toxicity Risk: The findings highlight that mitochondrial TrpRS is mechanistically similar to bacterial TrpRS. Antibiotics targeting bacterial TrpRS via this specific Mg²⁺-dependent mechanism pose a genuine risk of mitochondrial dysfunction, a known cause of neurodegenerative diseases (e.g., Parkinson's).
• Mechanistic Insight: The paper provides a definitive structural and thermodynamic explanation for how indolmycin acts as a "molecular trap." By forcing the catalytic metal into a stable, non-reactive coordination geometry via the OXA ring, the inhibitor effectively halts catalysis without competing directly with the substrate in the same way traditional competitive inhibitors do.
• Evolutionary Context: The work reinforces the evolutionary link between mitochondria and bacteria, showing that HmtTrpRS retains the ancestral bacterial mechanism for substrate recognition and metal coordination, which was lost or altered in the eukaryotic cytosolic lineage.

Conclusion: The paper establishes that HmtTrpRS is a tight-binding target for indolmycin, dependent on a specific Mg²⁺•ATP coordination state. This shared mechanism with bacterial enzymes explains the potential for mitochondrial toxicity of TrpRS-targeting antibiotics and provides a structural blueprint for designing safer, more selective therapeutics.